Optimization and performance evaluation of peptide-loaded monolithic poly-ε-caprolactone microspheres in mice bearing melanoma B16F1

B. Denish Shenoy, M. Venkatesh, N. Udupa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The objective of this investigation was to develop a bleomycin depot based on monolithic microparticulate technology to suppress tumour growth and to maintain constant plasma drag concentrations within an optimal therapeutic window over a prolonged period of time. Formulations were optimized with biodegradable poly-ε-carpolactone and evaluated in vitro for physicochemical characteristics, drug release in phosphate buffered saline (pH 7.4) and evaluated in vivo in tumour beating mice. This investigation revealed that upon subcutaneous injection, the biodegradable depot-forming poly-ε-carpolactone microspheres controlled drag release and suppressed tumour growth kinetics significantly compared to control. A preliminary pharmacokinetic evaluation exhibited steady plasma drag concentrations during the study period. This formulation with its reduced frequency of administration and better control of drag disposition is expected to provide an economic benefit to the user compared with products currently available for chemotherapy.

Original languageEnglish
Pages (from-to)256-260
Number of pages5
JournalPharmazie
Volume57
Issue number4
Publication statusPublished - 2002

Fingerprint

Bearings (structural)
Microspheres
Drag
Melanoma
Tumors
Peptides
Neoplasms
Bleomycin
Subcutaneous Injections
Growth
Plasmas
Pharmacokinetics
Chemotherapy
Growth kinetics
Phosphates
Economics
Technology
Drug Therapy
polycaprolactone
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Drug Discovery
  • Organic Chemistry
  • Chemistry(all)
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science

Cite this

@article{90705d72c8014192ab06ee6bad462d71,
title = "Optimization and performance evaluation of peptide-loaded monolithic poly-ε-caprolactone microspheres in mice bearing melanoma B16F1",
abstract = "The objective of this investigation was to develop a bleomycin depot based on monolithic microparticulate technology to suppress tumour growth and to maintain constant plasma drag concentrations within an optimal therapeutic window over a prolonged period of time. Formulations were optimized with biodegradable poly-ε-carpolactone and evaluated in vitro for physicochemical characteristics, drug release in phosphate buffered saline (pH 7.4) and evaluated in vivo in tumour beating mice. This investigation revealed that upon subcutaneous injection, the biodegradable depot-forming poly-ε-carpolactone microspheres controlled drag release and suppressed tumour growth kinetics significantly compared to control. A preliminary pharmacokinetic evaluation exhibited steady plasma drag concentrations during the study period. This formulation with its reduced frequency of administration and better control of drag disposition is expected to provide an economic benefit to the user compared with products currently available for chemotherapy.",
author = "Shenoy, {B. Denish} and M. Venkatesh and N. Udupa",
year = "2002",
language = "English",
volume = "57",
pages = "256--260",
journal = "Die Pharmazie",
issn = "0031-7144",
publisher = "Govi-Verlag Pharmazeutischer Verlag GmbH",
number = "4",

}

Optimization and performance evaluation of peptide-loaded monolithic poly-ε-caprolactone microspheres in mice bearing melanoma B16F1. / Shenoy, B. Denish; Venkatesh, M.; Udupa, N.

In: Pharmazie, Vol. 57, No. 4, 2002, p. 256-260.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Optimization and performance evaluation of peptide-loaded monolithic poly-ε-caprolactone microspheres in mice bearing melanoma B16F1

AU - Shenoy, B. Denish

AU - Venkatesh, M.

AU - Udupa, N.

PY - 2002

Y1 - 2002

N2 - The objective of this investigation was to develop a bleomycin depot based on monolithic microparticulate technology to suppress tumour growth and to maintain constant plasma drag concentrations within an optimal therapeutic window over a prolonged period of time. Formulations were optimized with biodegradable poly-ε-carpolactone and evaluated in vitro for physicochemical characteristics, drug release in phosphate buffered saline (pH 7.4) and evaluated in vivo in tumour beating mice. This investigation revealed that upon subcutaneous injection, the biodegradable depot-forming poly-ε-carpolactone microspheres controlled drag release and suppressed tumour growth kinetics significantly compared to control. A preliminary pharmacokinetic evaluation exhibited steady plasma drag concentrations during the study period. This formulation with its reduced frequency of administration and better control of drag disposition is expected to provide an economic benefit to the user compared with products currently available for chemotherapy.

AB - The objective of this investigation was to develop a bleomycin depot based on monolithic microparticulate technology to suppress tumour growth and to maintain constant plasma drag concentrations within an optimal therapeutic window over a prolonged period of time. Formulations were optimized with biodegradable poly-ε-carpolactone and evaluated in vitro for physicochemical characteristics, drug release in phosphate buffered saline (pH 7.4) and evaluated in vivo in tumour beating mice. This investigation revealed that upon subcutaneous injection, the biodegradable depot-forming poly-ε-carpolactone microspheres controlled drag release and suppressed tumour growth kinetics significantly compared to control. A preliminary pharmacokinetic evaluation exhibited steady plasma drag concentrations during the study period. This formulation with its reduced frequency of administration and better control of drag disposition is expected to provide an economic benefit to the user compared with products currently available for chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0036218429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036218429&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 256

EP - 260

JO - Die Pharmazie

JF - Die Pharmazie

SN - 0031-7144

IS - 4

ER -